A signature of four circulating micrornas as potential biomarkers for diagnosing early-stage breast cancer
Fiche du document
24 janvier 2025
- 10938/28802
- 34204158.0
- 2-s2.0-85107271667
Ce document est lié à :
International Journal of Molecular Sciences
Mots-clés
Breast cancer Circulating biomarkers Diagnosis Early stage Liquid biopsy Microrna Roc curve Adult Aged Aged, 80 and over Biomarkers, tumor Breast neoplasms Circulating microrna Female Gene expression profiling Gene expression regulation, neoplastic Humans Middle aged Neoplasm staging Statistics, nonparametric Young adult Biological marker Epidermal growth factor receptor 2 Estrogen receptor Microrna 100 Microrna 125b Microrna 130a Microrna 139 5p Microrna 145 Microrna 155 Microrna 182 Microrna 195 Microrna 21 Microrna 23a Microrna 425 5p Microrna 451 Oral contraceptive agent Progesterone receptor Unclassified drug Tumor marker Alcohol consumption Article Body mass Breast carcinoma Cancer patient Cancer size Cancer staging Cigarette smoking Clinical article Controlled study Diagnostic accuracy Diagnostic test accuracy study Distant metastasis Dna microarray Down regulation Early cancer Early diagnosis Genetic marker Hormone substitution Human Human tissue Lymph node metastasis Mammography Practice guideline Protein expression Real time polymerase chain reaction Rna extraction Rna microarray Sensitivity and specificity Upregulation Very elderly Youden index Blood Breast tumor Gene expression regulation Genetics Nonparametric test PathologySujets proches
Carcinoma Cancers Malignancy (Cancer) Malignant tumorsCiter ce document
Itani et al., « A signature of four circulating micrornas as potential biomarkers for diagnosing early-stage breast cancer », American University of Beirut ScholarWorks
Partage / Export
Résumé
Breast cancer (BC) is the most predominant type of cancer among women. The aim of this study is to find new biomarkers that can help in early detection of BC, especially for those who are too young to be screened using mammography as per guidelines. Using microRNA microarray, we previously showed dysregulation of 74 microRNAs in tumors from early BC patients as compared with normal adjacent tissues, which we were interested in studying in blood circulation. In this study, we investigated the expression of 12 microRNA (miR-21/miR-155/miR-23a/miR-130a/miR-145/miR-425-5p/miR-139-5p/miR-451/miR-195/miR-125b/miR-100, and miR-182) in the plasma of 41 newly diagnosed Lebanese BC patients with early invasive ductal carcinoma as compared with 32 healthy controls. Total RNA was extracted from plasma, and expression levels of miRNA of interest were measured using RT-qPCR followed by statistical analysis; miR-21, miR-155, miR-23a, miR-130a, miR-145, miR-425-5p, and miR-139-5p were significantly upregulated and miR-451 was significantly downregulated, in the plasma of BC patients as compared with healthy controls. The positively correlated miR-23a, miR-21, and miR-130a had a high diagnostic accuracy (86%). Importantly, the combination of miR-145/miR-425-5p/miR-139-5p/miR-130a scored the highest diagnostic accuracy of 95% with AUC = 0.97 (sensitivity 97% and specificity 91%). MicroRNAs are promising non-invasive diagnostic biomarkers for early-stage BC with the panel of miR-145/miR-425-5p/miR-139-5p/miR-130a having the highest diagnostic accuracy. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.
